Historical Valuation
Kyverna Therapeutics Inc (KYTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.51. The fair price of Kyverna Therapeutics Inc (KYTX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：8.32
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Kyverna Therapeutics Inc (KYTX) has a current Price-to-Book (P/B) ratio of 2.53. Compared to its 3-year average P/B ratio of 0.97 , the current P/B ratio is approximately 161.72% higher. Relative to its 5-year average P/B ratio of 0.97, the current P/B ratio is about 161.72% higher. Kyverna Therapeutics Inc (KYTX) has a Forward Free Cash Flow (FCF) yield of approximately -31.49%. Compared to its 3-year average FCF yield of -54.43%, the current FCF yield is approximately -42.14% lower. Relative to its 5-year average FCF yield of -54.43% , the current FCF yield is about -42.14% lower.
P/B
Median3y
0.97
Median5y
0.97
FCF Yield
Median3y
-54.43
Median5y
-54.43
Competitors Valuation Multiple
AI Analysis for KYTX
The average P/S ratio for KYTX competitors is 1.51, providing a benchmark for relative valuation. Kyverna Therapeutics Inc Corp (KYTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for KYTX
1Y
3Y
5Y
Market capitalization of KYTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of KYTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is KYTX currently overvalued or undervalued?
Kyverna Therapeutics Inc (KYTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.51. The fair price of Kyverna Therapeutics Inc (KYTX) is between to according to relative valuation methord.
What is Kyverna Therapeutics Inc (KYTX) fair value?
KYTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kyverna Therapeutics Inc (KYTX) is between to according to relative valuation methord.
How does KYTX's valuation metrics compare to the industry average?
The average P/S ratio for KYTX's competitors is 1.51, providing a benchmark for relative valuation. Kyverna Therapeutics Inc Corp (KYTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Kyverna Therapeutics Inc (KYTX) as of Jan 10 2026?
As of Jan 10 2026, Kyverna Therapeutics Inc (KYTX) has a P/B ratio of 2.53. This indicates that the market values KYTX at 2.53 times its book value.
What is the current FCF Yield for Kyverna Therapeutics Inc (KYTX) as of Jan 10 2026?
As of Jan 10 2026, Kyverna Therapeutics Inc (KYTX) has a FCF Yield of -31.49%. This means that for every dollar of Kyverna Therapeutics Inc’s market capitalization, the company generates -31.49 cents in free cash flow.
What is the current Forward P/E ratio for Kyverna Therapeutics Inc (KYTX) as of Jan 10 2026?
As of Jan 10 2026, Kyverna Therapeutics Inc (KYTX) has a Forward P/E ratio of -2.42. This means the market is willing to pay $-2.42 for every dollar of Kyverna Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Kyverna Therapeutics Inc (KYTX) as of Jan 10 2026?
As of Jan 10 2026, Kyverna Therapeutics Inc (KYTX) has a Forward P/S ratio of 0.00. This means the market is valuing KYTX at $0.00 for every dollar of expected revenue over the next 12 months.